ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting Marseille, France, December 5 ...
Eligible consumers have until Dec. 18 to sign on to a class action settlement to get part of a $177 million payout for a ...
Company will host conference call and live webcast to review and discuss the data at 8:00 am ETNORWOOD, Mass., Dec. 10, 2025 ...
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistan ...
Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as ...
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, ...
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...
Lawrence school board members reviewed data on Monday showing that more than 2,100 students entered or left the district last ...
MBX Biosciences, Inc. is rated a Buy, driven by canvuparatide's once-weekly dosing advantage in hypoparathyroidism. Learn ...
Title: Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) Session: ...
Newport News has been busy behind the scenes preparing to attract a data center to the city, including buying land for ...
Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback